journal article·2026-06-02

Nose-to-Brain Delivery of mRNA-Loaded Lipid Nanoparticles Bypasses the Blood–Brain Barrier for Effective Brain Disease Therapy

Xiaolu Yu, Xiao-Meng Deng, Yi Lin, Hongyu Ren, Lu Jia, Yanan Meng, Fan Liu, Qiang Cheng, Zhao-Qian Teng, Tuo Wei

ACS Nano· Volume 20· Issue 21
Publisher page

Abstract

mRNA-loaded lipid nanoparticles (mRNA-LNPs) show great therapeutic potential, but their use in central nervous system (CNS) disorders is limited by poor blood–brain barrier (BBB) penetration. Intranasal (IN) administration can bypass the BBB via olfactory/trigeminal pathways, enabling direct brain targeting and rapid screening of brain-specific lipid nanoparticles (LNPs). Using a peptide-based ionizable lipid platform, we systematically evaluated how LNP surface charge affects IN brain delivery and found that positively charged mRNA-LNPs produced superior brain transfection. Iterative in vivo screening yielded an intranasal brain-targeting LNP (INBT LNP) that efficiently traverses the olfactory and trigeminal nerves, drives brain-specific mRNA expression, and minimizes off-target expression in peripheral organs. Co-delivery of mRNAs encoding brain-derived neurotrophic factor (BDNF) and interleukin-10 (IL-10) using INBT LNPs significantly reduced neuroinflammation, inhibited neuronal death, and improved cognition in a repetitive mild traumatic brain injury (rmTBI) mouse model. Overall, this work establishes a noninvasive, patient-compliant, intranasal mRNA-LNP platform for brain delivery, offering a promising therapeutic strategy for TBI and other CNS disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology

Chinese Academy of Sciences

Beijing Institute for Stem Cell and Regenerative Medicine

University of Chinese Academy of Sciences

Department of Biomedical Engineering, College of Future Technology

Peking University

Beijing Advanced Center of RNA Biology

Funding

Hebei Natural Science Foundation · Strategic Priority Research Program of the Chinese Academy of Sciences · Project from Beijing Institute for Stem Cell and Regenerative Medicine · Noncommunicable Chronic Diseases-National Science and Technology Major Project · National Key Research and Development Program of China · Initiative Scientific Research Program, Institute of Zoology, CAS · The Open Research Fund of Beijing Advanced Center of RNA Biology (BEACON) at Peking University

References (52)

Show source-provided references
1. 10.1038/nbt.173310.1038/nbt.1733 ↗
2. 10.1186/s12929-023-00977-510.1186/s12929-023-00977-5 ↗
3. 10.1038/s43586-023-00246-710.1038/s43586-023-00246-7 ↗
4. 10.1038/s41573-024-00977-610.1038/s41573-024-00977-6 ↗
5. 10.1038/s41565-021-00898-010.1038/s41565-021-00898-0 ↗
6. 10.1038/mt.2010.8510.1038/mt.2010.85 ↗
7. 10.1038/s41565-023-01563-410.1038/s41565-023-01563-4 ↗
8. 10.1038/s41570-025-00770-y10.1038/s41570-025-00770-y ↗
9. 10.1038/s41573-021-00139-y10.1038/s41573-021-00139-y ↗
10. 10.1038/s41583-024-00829-710.1038/s41583-024-00829-7 ↗
11. 10.1126/sciadv.adw073010.1126/sciadv.adw0730 ↗
12. 10.1021/acs.nanolett.4c0518610.1021/acs.nanolett.4c05186 ↗
13. 10.1038/s41563-024-02114-510.1038/s41563-024-02114-5 ↗
14. 10.1021/acsnano.4c1100610.1021/acsnano.4c11006 ↗
15. 10.1021/acsnano.5c0892810.1021/acsnano.5c08928 ↗
16. 10.1517/17425247.2014.89769310.1517/17425247.2014.897693 ↗
17. 10.1007/s13311-017-0520-410.1007/s13311-017-0520-4 ↗
18. 10.1602/neurorx.2.1.310.1602/neurorx.2.1.3 ↗
19. 10.1084/jem.2019006210.1084/jem.20190062 ↗
20. 10.1038/s41598-020-65972-410.1038/s41598-020-65972-4 ↗
21. 10.1186/s40478-021-01161-210.1186/s40478-021-01161-2 ↗
22. 10.1177/0271678X1770146010.1177/0271678X17701460 ↗
23. 10.1177/096368971771409210.1177/0963689717714092 ↗
24. 10.1016/j.jconrel.2023.12.05410.1016/j.jconrel.2023.12.054 ↗
25. 10.1016/j.neuroscience.2004.05.02910.1016/j.neuroscience.2004.05.029 ↗
26. 10.1016/j.apmt.2022.10163110.1016/j.apmt.2022.101631 ↗
27. 10.1002/advs.20190290610.1002/advs.201902906 ↗
28. 10.1002/smll.20220318210.1002/smll.202203182 ↗
29. 10.1002/adma.20250059810.1002/adma.202500598 ↗
30. 10.1016/j.cell.2025.01.01710.1016/j.cell.2025.01.017 ↗
31. 10.1002/adma.20251881410.1002/adma.202518814 ↗
32. 10.1021/acs.molpharmaceut.0c0017010.1021/acs.molpharmaceut.0c00170 ↗
33. 10.1038/s41563-025-02320-910.1038/s41563-025-02320-9 ↗
34. 10.1002/adma.20120180010.1002/adma.201201800 ↗
35. 10.1016/j.addr.2017.09.02310.1016/j.addr.2017.09.023 ↗
36. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
37. 10.1126/sciadv.abd688910.1126/sciadv.abd6889 ↗
38. 10.1016/j.neuron.2017.07.01010.1016/j.neuron.2017.07.010 ↗
39. 10.4103/1673-5374.19896410.4103/1673-5374.198964 ↗
40. 10.1615/CritRevImmunol.v21.i5.2010.1615/CritRevImmunol.v21.i5.20 ↗
41. 10.1016/j.biocel.2004.02.02310.1016/j.biocel.2004.02.023 ↗
42. 10.3389/fphys.2021.74093910.3389/fphys.2021.740939 ↗
43. 10.1016/0165-5728(90)90061-Q10.1016/0165-5728(90)90061-Q ↗
44. 10.1016/j.expneurol.2015.08.01810.1016/j.expneurol.2015.08.018 ↗
45. 10.1016/j.expneurol.2012.09.01210.1016/j.expneurol.2012.09.012 ↗
46. 10.1002/glia.2467110.1002/glia.24671 ↗
47. 10.1038/s41570-025-00770-y10.1038/s41570-025-00770-y ↗
48. 10.1602/neurorx.2.1.310.1602/neurorx.2.1.3 ↗
49. 10.1111/ner.1253810.1111/ner.12538 ↗
50. 10.1176/appi.ajp.159.8.131510.1176/appi.ajp.159.8.1315 ↗
51. 10.1089/neu.2010.135810.1089/neu.2010.1358 ↗
52. 10.1002/adma.20240981210.1002/adma.202409812 ↗